drugset
drugset / Trial / NCT02154308

Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Adults

NCT02154308 ↗

Phase 3 Completed 787 enrolled Il-Yang Pharm. Co., Ltd.
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the safety and immunogenicity of IL-YANG Inactivated Split Influenza Vaccine (IL-YANG FLU Vaccine Prefilled Syringe INJ.) administered as a single intramuscular injection.

Timeline

Start
2012-11
Primary completion
2013-03
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject IL-YANG Inactivated Split Influenza Vaccine Vaccine 0.5 ml Intramuscular

Indications

No indication recorded.